Emily Walsh Martin, PhD, spoke with Amber Freed, founder and CEO of SLC6A1 Connect, a patient organization focused on accelerating the development of therapies for SLC6A1 patients like her son Maxwell.

ASGCT 2026 Abstract Highlights with Emily Walsh Martin, Sanjay D’Souza, and Jason West
43:06

The Issue – A Caregiver’s Journey from Development to Treatment with Amber Freed, Founder of SLC6A1 Connect
41:51

CGMP iPSC-derived myogenic progenitor product for the treatment of muscular dystrophies with Joseph Glorioso and Rita Perlingeiro
39:58